Hunan Erkang Pharmaceutical Co., Ltd. was established in 2003. It is an excellent high-tech listed enterprise (SZ.300267) with a large scale, many varieties and complete supporting facilities in China's pharmaceutical excipients industry. It is an important developer of the standards for China's pharmaceutical excipients industry and Promoter.

With the mission of "everything is for the safety of drugs", the company adheres to the dual-main business driving strategy of "medicine + new energy", and relies on the "National Medical Excipient Engineering Technology Research Center", "National Enterprise Technology Center" and "National Drug Administration Drug Administration High-standard national scientific research platforms such as Key Laboratory for Engineering Technology for Excipients" are guided by technological innovation and driven by drug quality and safety and industry standards. They have developed into a combination of pharmaceutical intermediates, raw materials, pharmaceutical auxiliary materials, and pharmaceutical auxiliary materials. A comprehensive multinational enterprise group integrating pharmaceutical preparations, traditional Chinese medicine, big health and new energy industries.

The company is an excellent enterprise in China's pharmaceutical auxiliary materials industry. It has 129 pharmaceutical auxiliary materials, 75 raw materials and 295 finished drug approval numbers. Among them, starch plant capsules are core products with global independent intellectual property rights. They have internationally leading technology and are a major breakthrough in the world capsule industry. More than 100 patents have been applied for at home and abroad. The company is planning to expand the new energy field under the strategic goal of "dual carbon", builds a full industrial chain of lithium battery positive electrode materials across borders, and focuses on promoting the extension of lithium mineral resources in Nigeria, Africa, and provides the industry with a stable and high-quality lithium resource series products. At present, the company has a production and research and development base for pharmaceutical and lithium series products in countries and regions along the "Belt and Road", and its products cover more than 30 countries and regions.

In the future, Erkang Pharmaceutical will adhere to the original aspirations of pharmaceutical people, focus on drug safety and new energy development, and through the dual main business driving strategy of "pharmaceutical + new energy", actively build an integrated industrial ecosystem of "raw and auxiliary materials + preparations" to promote corporate value. Continuously improve and create a national enterprise brand with international influence.